Press Release: Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) ("Ocuphire"), a clinical-st

Dow JonesApr 22 20:00

Ocuphire Pharma Incentivizes Director Pepose With Stocks and Options

TipRanksApr 18 04:32

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%

BenzingaApr 12 04:31

Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment

Ocuphire Pharma (OCUP) enrolled the first patient in the phase 3 trial of its Phentolamine Ophthalmic Solution 0.75% for the treatment of decreased visual acuity under low light conditions following k

MT NewswiresApr 12 02:28

Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)

TipRanksApr 2 19:20

Ocuphire Announces the US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by Its Partner Viatris

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disor

BenzingaApr 1 19:17